Alcon has entered into a definitive agreement to acquire ESBATech AG for $150 million in cash at closing, plus achievement-based R&D payments of as much as $439 million. ESBATech is a Swiss clinical-stage biotechnology company developing a pipeline of single-chain antibody fragment therapeutics for topical and local delivery. ESBATech has several stable and soluble single-chain antibody fragments in development, as well as a product candidate that has progressed into Phase I and II studie...